报告题目：基于CRISPR-Cas系统的分子诊断与新冠病毒检测和分型 (CRISPR-Cas System for Detection and Genotyping
报 告 人：唐时幸 （Tang, Shixing）
Outbreak of SARS-CoV-2 infection has become an ongoing global pandemic. One of the challenges is to develop rapid, portable, and accurate testing methods. The emergence of more transmissible and/or more virulent SARS-CoV-2 variants of concern (VOCs) or variants of interesting (VOIs) has triggered intensive genomic surveillance, which is costly and difficult to sustain operationally over the long-term. The current gold-standard diagnostic for SARS-CoV-2 infection, quantitative reverse transcription polymerase chain reaction (RT-qPCR), has been well established and widely used for screening. However, it is believed that frequent testing with a fast turnaround time is required to break the current pandemic. The need for SARS-CoV-2 tests that are rapid, widespread, and able to identify infectious individuals has motivated efforts to explore new strategies for viral RNA detection. CRISPR diagnostics based on CRISPR technology can augment gold-standard PCR-based testing. The principle, assay formats and applications of CRISPR-based diagnostics will be discussed. The in-house assay to distinguish VOCs or VOIs of SARS-CoV-2 will be presented.